Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
21
BMGL Quote, Financials, Valuation and Earnings
Last price:
$0.97
Seasonality move
:
--
Day range:
$1.01 - $1.09
52-week range:
$0.91 - $9.40
Dividend yield:
0%
P/E ratio:
294.67x
P/S ratio:
2.31x
P/B ratio:
7.67x
Volume:
85.2K
Avg. volume:
46.5K
1-year change:
--
Market cap:
$19.7M
Revenue:
$8.5M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | -- | -- | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
$130K | -$0.04 | -- | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -- | -- | -- |
|
WVE
Wave Life Sciences Ltd.
|
$7.7M | -$0.31 | -78.95% | -36.52% | $19.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BMGL
Basel Medical Group Ltd.
|
$1.05 | -- | $19.7M | 294.67x | $0.00 | 0% | 2.31x |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
$1.77 | -- | $20.8M | -- | $0.00 | 0% | 120.01x |
|
MNDR
Mobile-health Network Solutions
|
$1.52 | -- | $1.9M | -- | $0.00 | 0% | 0.14x |
|
WVE
Wave Life Sciences Ltd.
|
$7.49 | $19.80 | $1.3B | -- | $0.00 | 0% | 11.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BMGL
Basel Medical Group Ltd.
|
-- | 0.000 | -- | -- |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | 0.000 | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -0.681 | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -0.831 | -- | 2.20x |
|
WVE
Wave Life Sciences Ltd.
|
12.99% | 1.535 | 1.67% | 2.40x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BMGL
Basel Medical Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CUPR
Cuprina Holdings (Cayman)
|
-- | -- | -- | -- | -- | -- |
|
GDTC
CytoMed Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -1223.46% | -1223.46% | -- | -- |
|
WVE
Wave Life Sciences Ltd.
|
$5.4M | -$56.4M | -64.6% | -73.8% | -740.71% | -$46.1M |
Basel Medical Group Ltd. vs. Competitors
-
Which has Higher Returns BMGL or CUPR?
Cuprina Holdings (Cayman) has a net margin of -- compared to Basel Medical Group Ltd.'s net margin of --. Basel Medical Group Ltd.'s return on equity of -- beat Cuprina Holdings (Cayman)'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMGLBasel Medical Group Ltd.-- -- -- CUPRCuprina Holdings (Cayman)-- -- -- -
What do Analysts Say About BMGL or CUPR?
Basel Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cuprina Holdings (Cayman) has an analysts' consensus of -- which suggests that it could fall by --. Given that Basel Medical Group Ltd. has higher upside potential than Cuprina Holdings (Cayman), analysts believe Basel Medical Group Ltd. is more attractive than Cuprina Holdings (Cayman).
Company Buy Ratings Hold Ratings Sell Ratings BMGLBasel Medical Group Ltd.0 0 0 CUPRCuprina Holdings (Cayman)0 0 0 -
Is BMGL or CUPR More Risky?
Basel Medical Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cuprina Holdings (Cayman) has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMGL or CUPR?
Basel Medical Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cuprina Holdings (Cayman) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basel Medical Group Ltd. pays -- of its earnings as a dividend. Cuprina Holdings (Cayman) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMGL or CUPR?
Basel Medical Group Ltd. quarterly revenues are --, which are smaller than Cuprina Holdings (Cayman) quarterly revenues of --. Basel Medical Group Ltd.'s net income of -- is lower than Cuprina Holdings (Cayman)'s net income of --. Notably, Basel Medical Group Ltd.'s price-to-earnings ratio is 294.67x while Cuprina Holdings (Cayman)'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basel Medical Group Ltd. is 2.31x versus -- for Cuprina Holdings (Cayman). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMGLBasel Medical Group Ltd.2.31x 294.67x -- -- CUPRCuprina Holdings (Cayman)-- -- -- --
-
Which has Higher Returns BMGL or GDTC?
CytoMed Therapeutics Ltd. has a net margin of -- compared to Basel Medical Group Ltd.'s net margin of --. Basel Medical Group Ltd.'s return on equity of -- beat CytoMed Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMGLBasel Medical Group Ltd.-- -- -- GDTCCytoMed Therapeutics Ltd.-- -- -- -
What do Analysts Say About BMGL or GDTC?
Basel Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CytoMed Therapeutics Ltd. has an analysts' consensus of -- which suggests that it could grow by 182.49%. Given that CytoMed Therapeutics Ltd. has higher upside potential than Basel Medical Group Ltd., analysts believe CytoMed Therapeutics Ltd. is more attractive than Basel Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BMGLBasel Medical Group Ltd.0 0 0 GDTCCytoMed Therapeutics Ltd.0 0 0 -
Is BMGL or GDTC More Risky?
Basel Medical Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CytoMed Therapeutics Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMGL or GDTC?
Basel Medical Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoMed Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basel Medical Group Ltd. pays -- of its earnings as a dividend. CytoMed Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMGL or GDTC?
Basel Medical Group Ltd. quarterly revenues are --, which are smaller than CytoMed Therapeutics Ltd. quarterly revenues of --. Basel Medical Group Ltd.'s net income of -- is lower than CytoMed Therapeutics Ltd.'s net income of --. Notably, Basel Medical Group Ltd.'s price-to-earnings ratio is 294.67x while CytoMed Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basel Medical Group Ltd. is 2.31x versus 120.01x for CytoMed Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMGLBasel Medical Group Ltd.2.31x 294.67x -- -- GDTCCytoMed Therapeutics Ltd.120.01x -- -- --
-
Which has Higher Returns BMGL or MNDR?
Mobile-health Network Solutions has a net margin of -- compared to Basel Medical Group Ltd.'s net margin of --. Basel Medical Group Ltd.'s return on equity of -- beat Mobile-health Network Solutions's return on equity of -1223.46%.
Company Gross Margin Earnings Per Share Invested Capital BMGLBasel Medical Group Ltd.-- -- -- MNDRMobile-health Network Solutions-- -- $4.1M -
What do Analysts Say About BMGL or MNDR?
Basel Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mobile-health Network Solutions has an analysts' consensus of -- which suggests that it could grow by 20952.63%. Given that Mobile-health Network Solutions has higher upside potential than Basel Medical Group Ltd., analysts believe Mobile-health Network Solutions is more attractive than Basel Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BMGLBasel Medical Group Ltd.0 0 0 MNDRMobile-health Network Solutions0 0 0 -
Is BMGL or MNDR More Risky?
Basel Medical Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mobile-health Network Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMGL or MNDR?
Basel Medical Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mobile-health Network Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basel Medical Group Ltd. pays -- of its earnings as a dividend. Mobile-health Network Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMGL or MNDR?
Basel Medical Group Ltd. quarterly revenues are --, which are smaller than Mobile-health Network Solutions quarterly revenues of --. Basel Medical Group Ltd.'s net income of -- is lower than Mobile-health Network Solutions's net income of --. Notably, Basel Medical Group Ltd.'s price-to-earnings ratio is 294.67x while Mobile-health Network Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basel Medical Group Ltd. is 2.31x versus 0.14x for Mobile-health Network Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMGLBasel Medical Group Ltd.2.31x 294.67x -- -- MNDRMobile-health Network Solutions0.14x -- -- --
-
Which has Higher Returns BMGL or WVE?
Wave Life Sciences Ltd. has a net margin of -- compared to Basel Medical Group Ltd.'s net margin of -707.83%. Basel Medical Group Ltd.'s return on equity of -- beat Wave Life Sciences Ltd.'s return on equity of -73.8%.
Company Gross Margin Earnings Per Share Invested Capital BMGLBasel Medical Group Ltd.-- -- -- WVEWave Life Sciences Ltd.70.69% -$0.32 $152.2M -
What do Analysts Say About BMGL or WVE?
Basel Medical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Wave Life Sciences Ltd. has an analysts' consensus of $19.80 which suggests that it could grow by 164.35%. Given that Wave Life Sciences Ltd. has higher upside potential than Basel Medical Group Ltd., analysts believe Wave Life Sciences Ltd. is more attractive than Basel Medical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BMGLBasel Medical Group Ltd.0 0 0 WVEWave Life Sciences Ltd.13 1 0 -
Is BMGL or WVE More Risky?
Basel Medical Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Wave Life Sciences Ltd. has a beta of -1.719, suggesting its less volatile than the S&P 500 by 271.88%.
-
Which is a Better Dividend Stock BMGL or WVE?
Basel Medical Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Wave Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Basel Medical Group Ltd. pays -- of its earnings as a dividend. Wave Life Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMGL or WVE?
Basel Medical Group Ltd. quarterly revenues are --, which are smaller than Wave Life Sciences Ltd. quarterly revenues of $7.6M. Basel Medical Group Ltd.'s net income of -- is lower than Wave Life Sciences Ltd.'s net income of -$53.9M. Notably, Basel Medical Group Ltd.'s price-to-earnings ratio is 294.67x while Wave Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Basel Medical Group Ltd. is 2.31x versus 11.43x for Wave Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMGLBasel Medical Group Ltd.2.31x 294.67x -- -- WVEWave Life Sciences Ltd.11.43x -- $7.6M -$53.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is down 12.74% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 62.68% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.8% over the past day.
